Dengue and Japanese encephalitis

Current Opinion in Infectious Diseases

Volumn 9, Issue 5, 1996, Pages 308-312

  Hayes, Curtis G ^a   Halstead, Scott B ^b  

^a NAVAL MEDICAL RESEARCH INSTITUTE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY RNA; JAPANESE ENCEPHALITIS VACCINE;

DENGUE; DENGUE VIRUS; EPIDEMIC ENCEPHALITIS; GENE TECHNOLOGY; HOST RESISTANCE; HUMAN; JAPANESE ENCEPHALITIS VIRUS; MOLECULAR BIOLOGY; MOSQUITO; NONHUMAN; SHORT SURVEY; VIRAL GENETICS; VIRUS REPLICATION;

EID: 0029841974     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199610000-00005     Document Type: Short Survey

References (30)

1. Tan B-H, Fu J, Sugrue RJ, Yap E-H, Chan Y-C, Tan YH: Recombinant dengue type 1 virus NS5 protein expressed in Escherichia coli exhibits RNA-dependent RNA polymerase activity. Virology 1996, 216:317-325. This is the first direct demonstration that the NS5 protein alone can serve as the RNA-dependent RNA polymerase for dengue viruses. This advance could make it easier to investigate factors involved in the regulation of dengue virus replication and to screen for drugs that inhibit polymerase activity.
2. Kapoor M, Zhang L, Ramachandra M, Kusukawa J, Ebner KE, Padmanaban R: Association between NS3 and NS5 proteins of dengue virus type 2 in the putative RNA replicase is linked to differential phosphorylation of NS5. J Biol Chem 1995, 270:19100-19106.
3. Jan L-R, Yang C-S, Trent DW, Falgout B, Lai C-J: Processing of Japanese encephalitis virus non-structural proteins: NS2B-NS3 complex and heterologous proteases. J Gen Virol 1995, 76:573-580.
4. Kapoor M, Zhang P. Mohan PM, Padmanabhan R: Synthesis and characterization of an infectious dengue virus type 2 RNA genome (New Guinea C strain). Gene 1995, 162:175-180. Dengue 2 joins the growing list of flaviviruses that have been expressed as full-length infectious cDNA clones. If mutations responsible for loss of virulence are defined, these clones will be useful in genetically engineering live-attenuated vaccines.
5. Cahour A, Pletnev A, Vazzeille-Falcoz M, Rosen L, Lai C-J: Growth-restricted dengue virus mutants in the 5′ non-coding region of the RNA genome. Virology 1995, 207:68-76.
6. Chen W, Kawano H, Men R, Clark D, Lai C-J: Construction of intertypic chimeric dengue viruses exhibiting type 3 antigenicity and neurovirulence for mice. J Virol 1995, 69:5186-5190. Two amino acid substitutions were made in the dengue 3 part of the chimeric dengue 3-dengue 4 virus constructed in this study. One of these changes, the substitution of lysine for glutamine at amino acid site 406 in the envelope gene, led to the acquisition of mouse neurovirulence in the mutant chimera.
7. Sumiyoshi H, Tignor GH, Shope RE: Characterization of a highly attenuated Japanese encephalitis virus generated from molecularly cloned cDNA. J Infect Dis 1995, 171:1144-1151. Six full-length cDNA clones of the Japanese virus genome were constructed by in-vitro ligation of different cDNA fragments containing the 3′ or 5′ halves of the genome. Three of the recombinant viruses produced from the full-length cDNA clones by RNA transcription were attenuated for mice. One of the attenuated strains was shown to have a single point mutation, the substitution of lysine for glutamic acid at amino acid site 138 in the envelope protein. This recombinant virus remained highly immunogenic, but no longer killed mice either by the intracranial or subcutaneous routes.
8. Fonseca BAL, Pincus S, Shope RE, Paoletti E, Mason PW: Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice. Vaccine 1994, 12:279-285.
9. Srivastava AK, Putnak JR, Warren RL, Hoke CH: Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection. Vaccine 1995, 13:1251-1258.
10. Seif SA, Morita K, Matsuo S, Hasebe F, Igarashi A: Finer mapping of neutralizing epitope(s) on the C-terminal of Japanese encephalitis virus E-protein expressed in recombinant Escherichia coli system. Vaccine 1995, 13:1515-1521.
11. + cytotoxic T lymphocyte clones established from a dengue 4-immune adult exhibited three patterns of reactivity: dengue 4-specific, crossreactive for dengue 2 and dengue 4, and crossreactive for all four serotypes of dengue virus. Several of the dengue 4-specific and one of the dengue 2-dengue 4 crossreactive clones were shown to recognize the same 9 amino acid peptide on the dengue 4 non-structural protein NS3, but the crossreactive clone used a different T cell receptor. These cytotoxic T lymphocyte clones were shown to be restricted by the HLA-B35 allele.
12. + human cytotoxic T lymphocyte clones of heterogenous serotype specificities. J Exp Med 1995, 182:853-863.
13. + CD8 cytotoxic T lymphocyte clones. J Gen Virol 1995, 76:2243-2249.
14. + cytotoxic T lymphocyte clones were established by stimulating peripheral blood mononuclear cells from a dengue 4 immune donor with inactivated dengue 4 viral antigens. Seven of these clones were shown to recognize the dengue 4 capsid protein. A dengue 4-specific clone was shown to recognize an epitope between amino acids 47-55 of the capsid protein and several clones that reacted with both dengue 4 and dengue 2 recognized a separate epitope between amino acids 83-92.
15. Centers for Disease Control: Imported dengue - United States, 1993-1994. Morb Mortal Wkly Rep MMWR 1995, 44:353-356. In 1993 there were 57 cases and in 1994, 91 cases of dengue reported to state and federal health agencies. Cases occurred in American tourists who had travelled to the Caribbean islands, Mexico, Central America, Asia and Africa. Six patients were hospitalized, three with syndromes resembling DHF.
16. Sharp TW, Wallace MR, Hayes CG, Sanchez JL, DeFraites R, Arthur RR, Thornton SA, Batchelor RA, Rozmajzl PJ, Hanson PK et al.: Dengue fever in US troops during operation Restore Hope, Somalia, 1992-1993. Am J Trop Med Hyg 1995, 53:89-94. Fifty-nine of 129 febrile troops acquired dengue in Somalia less than 1 month after arrival. Although dengue is transmitted by a daytime-biting mosquito, the only positive risk factor for dengue infection was the failure to use bed nets. Most troops failed to take anti-mosquito precautions such as the use of insect repellents or the wearing of long-sleeved shirts.
17. Defraites R, Smoak B, Trofa A, Hoke C et al.: Dengue fever among US military personnel - Haiti, September-November, 1994. JAMA 1995, 273:14-15. Of 106 fever cases, 14 had dengue etiology (dengue 1 and 2 viruses), mostly acquired a very short time after arrival. Anti-mosquito measures adopted included use of ultra-low volume malathion insecticide in duty areas.
18. Setiawan MW, Samsi TK, Pool TN, Sugianto D, Wulur H: Gallbladder wall thickening in dengue hemorrhagic fever: An ultrasonographic study. J Clin Ultrasound 1995, 23:357-362. Abnormal thickening of the gallbladder wall was observed in 93.8% of children with DSS. This observation introduces a simple, rapid, non-invasive outpatient test which identifies serious vascular permeability and a need for immediate hospitalization and fluid therapy.
19. Rodriguez-Figueroa L, Rigau-Perez JG, Suarez EL, Reiter P: Risk factors for dengue infection during an outbreak in Yanes, Puerto, Rico in 1991. Am J Trop Med Hyg 1995, 52:496-502.
20. Putnam JL, Scott TW: The effect of multiple host contacts on the infectivity of dengue-2 virus-infected Aedes aegypti. J Parasitol 1995, 81:170-174. Probing a host five, 10 or 20 consecutive times did not reduce, but increased transmission of dengue 2 viruses by infected A. aegypti mosquitoes. Once infected, these mosquitoes are extremely efficient vectors.
21. Focks DA, Daniels E, Haile DG, Keesling JE: A simulation model of the epidemiology of urban dengue fever: literature analysis, model development preliminary validation, and samples of simulation results. Am J Trop Med Hyg 1995, 53:489-506.
22. Guzman MG, Deubel V, Pelegrino JL, Rosario D, Marrero M, Sariol C, Kouri G: Partial nucleotide and amino acid sequences of the envelope and the envelope non-structural protein-1 gene junction of four dengue 2 virus strains isolated during the 1981 Cuban epidemic. Am J Trop Med Hyg 1995, 52:241-246. Cuban dengue 2 strains closely resemble prototype New Guinea C and a Thai strain, but not the DHF-associated Jamaica 1981-Vietnam strains which have been circulating in the American tropics since the 1981 Cuban outbreak.
23. Zanotti PMdeA, Gould EA, Gao GF, Harvey PH, Holmes EC: Population dynamics of flaviviruses revealed by molecular phylogenies. Proc Natl Acad Sci USA 1996, 93:548-553. An analysis of the phylogeny of the complete envelope gene sequences of 123 tick- and mosquito-borne flaviviruses suggests an explosive radiation in the past 200 years. The mechanism of this radiation is presumed to be due to increasing host populations and major dispersals of viruses.
24. Holland JJ: Evolving virus plagues. Proc Natl Acad Sci USA 1996, 93:545-546. RNA viruses have a high rate of mutation caused by lack of efficient proofreading or mismatch repair systems. The author speculates that as a result of enhanced transmission, new dengue types have appeared and will continue to appear, 'causing' DHF/DSS and other new syndromes.
25. Raviprakash K, Liu K, Matteucci M, Wagner R, Riffenburgh R, Mitchell C: Inhibition of dengue virus by novel, modified antisense oligonucleotides. J Virol 1995, 69:69-74.
26. Olson KE, Higgs S, Gaines PJ, Powers AM, Davis BS, Kamrud KI, Carlson JO, Blair CD, Beaty BJ: Genetically engineered resistance to dengue 2 virus transmission in mosquitoes. Science 1996, 272:884-886. Antisense RNA for the pre-membrane region of the dengue gene was transduced into a female Aedes aegypti by a recombinant Sindbis virus which then blocked replication of dengue 2 virus. This is the first illustration of the creation of a genetically resistant vector mosquito.
27. Wittesjo B, Eitrem R, Niklasson B, Vene S, Mangiafico JA: Japanese encephalitis after a 10-day holiday in Bali [Letter]. Lancet 1995, 345:856.
28. Gambel JM, DeFraites RF, Hoke Jr CH, Brown A, Sanchez J, Karabatsos N, Tsai T, Meschievitz C: Japanese encephalitis vaccine: persistence of antibody up to 3 years after a three-dose primary series. J Infect Dis 1995, 171:1074.
29. Ohtaki E, Matsuishi T, Hirano Y, Maekawa K: Acute disseminated encephalomyelitis with Japanese Be encephalitis vaccine (Nakayama-Yoken and Beijing strains). J Neurol Neurosurg Psychiatr 1995, 59:316-317.
30. Hennessy S, Liu Z, Tsai TF, Strom BL, Wan CM, Liu HL, Wu TX, Yu HJ, Liu QM, Karabatsos N et al.: Effectiveness of a live-attenuated Japanese encephalitis vaccine. Lancet 1996, 347:1583-1587. Effectiveness of a live-attenuated Japanese encephalitis vaccine, SA 14-14-2, was studied in 56 hospitalized cases and 1299 village-matched controls from Sichuan Province, China. Sixty-eight per cent of cases and 47% of controls received no vaccine. Effectiveness for one dose was 61% and for two doses 97.5%.